Literature DB >> 8595151

Aromatase inhibitors--where are we now?

W R Miller1.   

Abstract

Mesh：

Substances：

Year:  1996        PMID： 8595151      PMCID： PMC2074470          DOI： 10.1038/bjc.1996.73

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  16 in total

Review 1.  Aromatase inhibitors in the treatment of advanced breast cancer.

Authors:  W R Miller
Journal:  Cancer Treat Rev       Date:  1989-06       Impact factor: 12.111

Review 2.  Endocrine treatment for breast cancers: biological rationale and current progress.

Authors:  W R Miller
Journal:  J Steroid Biochem Mol Biol       Date:  1990-11-30       Impact factor: 4.292

3.  Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.

Authors:  R Pérez Carrión; V Alberola Candel; F Calabresi; R T Michel; R Santos; T Delozier; P Goss; L Mauriac; F Feuilhade; M Freue
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

4.  Diabetes mellitus associated with epidemic of infectious hepatitis in Nigeria.

Authors:  F C Adi
Journal:  Br Med J       Date:  1974-02-02

5.  Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients.

Authors:  L M Demers
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

6.  The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer.

Authors:  L M Demers; A Lipton; H A Harvey; J Hanagan; M Mulagha; R J Santen
Journal:  J Steroid Biochem Mol Biol       Date:  1993-03       Impact factor: 4.292

7.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

Authors:  S R Johnston; I E Smith; D Doody; S Jacobs; H Robertshaw; M Dowsett
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer.

Authors:  A L Harris; M Dowsett; S L Jeffcoate; J A McKinna; M Morgan; I E Smith
Journal:  J Clin Endocrinol Metab       Date:  1982-10       Impact factor: 5.958

10.  Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells.

Authors:  R Hackenberg; I Turgetto; A Filmer; K D Schulz
Journal:  J Steroid Biochem Mol Biol       Date:  1993-11       Impact factor: 4.292
View more
  3 in total

1.  Elevated incidence of fractures in women with invasive breast cancer.

Authors:  B J Edwards; W J Gradishar; M E Smith; J A Pacheco; J Holbrook; J M McKoy; B Nardone; S Tica; V Godinez-Puig; A W Rademaker; I B Helenowski; A D Bunta; P H Stern; S T Rosen; D P West; T A Guise
Journal:  Osteoporos Int       Date:  2015-08-21       Impact factor: 4.507

2.  Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.

Authors:  H P Ciolino; T T Wang; N Sathyamoorthy
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

Review 3.  Estrogen biosynthesis and action in ovarian cancer.

Authors:  Felicitas Mungenast; Theresia Thalhammer
Journal:  Front Endocrinol (Lausanne)       Date:  2014-11-12       Impact factor: 5.555
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.